The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Immune checkpoint inhibitors (ICIs) with nivolumab and pembrolizumab are promising
agents for advanced hepatocellular carcinoma (HCC) but lack of effective biomarkers. We …

Simple Summary Immune checkpoint inhibitors are dramatically reshaping cancer
treatments in a multitude of advanced cancers, including hepatocellular carcinoma (HCC) …

Original research: Post-registration experience of nivolumab in advanced hepatocellular
carcinoma: an international study - PMC Back to Top Skip to main content NIH NLM Logo …

Abstract Treatment of patients with hepatocellular carcinoma (HCC) remains a serious
challenge due to high heterogeneity and limited treatment options. In the past few decades …

Nivolumab has shown durable response and safety in patients with hepatocellular
carcinoma (HCC) in previous trials. However, real-world data of nivolumab in HCC patients …

Background The clinical significance of programmed cell death protein-1 (PD-1)-targeted
immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety …

Methods Consecutive HCC patients who received regorafenib or nivolumab after failure of
sorafenib treatment were included. Primary endpoint was overall survival (OS) and …

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with
hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of …

Background Hepatocellular carcinoma (HCC) is one of the most lethal cancers. After many
years of stagnation, there are now several systemic treatments available for patients with …